Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Aug 25, 2026
Johnson & Johnson (JNJ): Can Shares Reach $300 (+10% Upside)?

Johnson & Johnson (JNJ): Can Shares Reach $300 (+10% Upside)?

Key Takeaways

  • Target in focus: $300, roughly 10% above Johnson & Johnson's recent price near $273 and matching the most bullish Wall Street price target.
  • Bullish case: Accelerating growth in Innovative Medicine, a maturing MedTech pipeline, and a prolonged rally that has lifted shares sharply off their 52-week low.
  • Key obstacle: $300 sits well above the Street's consensus target of roughly $255, implying the move depends on continued upward estimate revisions.
  • Technical backdrop: The all-time high near $275 is the first major resistance level to clear before $300 becomes realistic.
  • Bottom line: $300 is ambitious but not implausible over a multi-quarter horizon, contingent on sustained pipeline execution and favorable sentiment.

Why the $300 Level Matters

JNJ has quietly delivered one of the more remarkable large-cap healthcare recoveries of the past year. After trading near $173 in September 2025, the stock has climbed toward $273, putting its all-time high of roughly $275 within reach. As the shares flirt with record territory, a growing number of investors are asking whether the stock can push through the next major psychological milestone: $300.

The $300 level is not arbitrary. It represents the highest price target among the Wall Street analysts covering the company, a round-number threshold that captures retail attention, and a roughly 10% advance from current levels. That distance makes it a meaningful but not outlandish objective to debate.

Company Overview and Current Market Position

JNJ is a diversified healthcare conglomerate operating through two segments: Innovative Medicine (its pharmaceutical business) and MedTech (medical devices). The company carries a market capitalization of approximately $650 billion and trades at a price-to-earnings (P/E) ratio near 31, reflecting a premium multiple for what has historically been viewed as a defensive, slower-growth name.

The recent rerating reflects a meaningful shift in fundamentals. Innovative Medicine has delivered double-digit year-over-year growth, led by strength in oncology treatments such as DARZALEX, while the MedTech division continues to recover and expand its product portfolio, including progress on the OTTAVA robotic surgical system. Management has expressed confidence in its outlook, guided by full-year 2026 adjusted earnings per share (EPS) of roughly $11.43 to $11.63. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

What Could Drive the Next Leg Higher

Several catalysts could support a push toward $300. First, continued strength in Innovative Medicine, particularly in oncology and immunology, could keep revenue and EPS growth ahead of consensus expectations. A deeper pipeline — spanning treatments for multiple myeloma, lupus, and other conditions — provides multiple shots on goal for future growth.

Second, analysts have been consistently raising targets. Morgan Stanley upgraded the stock and lifted its price target to $262 from $200, citing stronger growth prospects relative to large-cap biopharma peers. This pattern of upward revisions, if it continues, could gradually pull the consensus target — currently near $255 — closer to the $300 mark.

Third, resolution of the company's long-running talc litigation has removed a significant overhang that had weighed on sentiment for years, allowing investors to focus on operating performance. From what I see, the pipeline momentum remains the key variable to watch.

What Could Prevent the Move

The primary obstacle is valuation and expectations. At a P/E near 31, the stock is no longer priced like a stodgy defensive name, which means any stumble in growth could trigger a de-rating. Patent expirations on key drugs remain a structural headwind, even if new products are offsetting those losses for now.

Additionally, the gap between the current price and the consensus analyst target is notable. With the average target near $255, the stock already trades above what most analysts consider fair value on a 12-month view. Reaching $300 would require the consensus itself to climb substantially, a process that typically unfolds only with repeated earnings beats and raised guidance.

Analyst Price Targets

Wall Street's views remain constructive but divided. The consensus 12-month price target sits near $255, with a low estimate around $190 and a high estimate of $300. The high target — associated with TD Cowen — aligns exactly with the level investors are now asking about. Notably, even the bullish $300 target implies only modest additional upside beyond the stock's all-time high, underscoring how far shares have already run.

Technical Levels That Matter

From a technical analysis perspective, the all-time high near $275 is the critical supply zone. A decisive break and hold above that level would establish new price discovery and could open the path toward $300. On the downside, the prior consolidation zone between roughly $255 and $265, along with the psychological $250 level, represents the first meaningful support area should momentum fade. I also checked this using Tickeron’s AI Pattern Search Engine to confirm the key levels.

Final Assessment

A move to $300 for JNJ is achievable but far from guaranteed. The strongest arguments in favor are the company's improving growth profile, a pipeline with multiple catalysts, and the steady climb in analyst price targets. The biggest risks are the stock's already-rich valuation, looming patent expirations, and the fact that it now trades above the Street's consensus target. Investors should monitor quarterly revenue and EPS trends, pipeline readouts, and whether the shares can hold above their prior all-time high before any sustained push toward $300 becomes realistic.

Tracking Momentum with AI Daily Buy/Sell Signals

For traders monitoring whether JNJ can sustain its momentum toward $300, I find Tickeron’s AI Daily Buy/Sell Signals a practical way to stay on top of shifting conditions. The platform uses artificial intelligence to generate Buy, Sell, or Hold signals based on technical patterns and market behavior, helping me track opportunities and existing positions more efficiently.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: JNJ

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Momentum Indicator for JNJ turns negative, indicating new downward trend

JNJ saw its Momentum Indicator move below the 0 level on September 16, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned negative. In 37 of the 83 cases, the stock moved further down in the following days. The odds of a decline are at 45%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for JNJ moved out of overbought territory on August 20, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 16 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 42%.

The Moving Average Convergence Divergence Histogram (MACD) for JNJ turned negative on September 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 17 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 36%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 40%.

JNJ broke above its upper Bollinger Band on September 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 27 of 52 cases where JNJ's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 52%.

Following a +1.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in 164 of 350 cases, the price rose further within the following month. The odds of a continued upward trend are 47%.

The Aroon Indicator entered an Uptrend today. In 127 of 261 cases where JNJ Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 49%.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 5 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock better than average.

The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.657) is normal, around the industry mean (19.050). P/E Ratio (31.321) is within average values for comparable stocks, (34.258). Projected Growth (PEG Ratio) (2.831) is also within normal values, averaging (5.614). Dividend Yield (0.020) settles around the average of (0.025) among similar stocks. P/S Ratio (6.658) is also within normal values, averaging (4.033).

The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 197.52B. The market cap for tickers in the group ranges from 4.8K to 1.03T. LLY holds the highest valuation in this group at 1.03T. The lowest valued company is NEWG at 4.8K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was 2%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was 15%. MIRA experienced the highest price growth at 8%, while GRFS experienced the biggest fall at -3%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was 178%. For the same stocks of the Industry, the average monthly volume growth was 32% and the average quarterly volume growth was -23%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 26
P/E Growth Rating: 55
Price Growth Rating: 52
SMR Rating: 59
Profit Risk Rating: 63
Seasonality Score: 0 (-100 ... +100)
View a ticker or compare two or three
JNJ
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

an investment holding company with interests in health care products

Industry PharmaceuticalsMajor

Profile
Details
Industry
Pharmaceuticals Major
Address
One Johnson & Johnson Plaza
Phone
+1 732 524-0400
Employees
138200
Web
https://www.jnj.com
Interact to see
Advertisement
Shares of ALDX are down about 73.02% in premarket trading, plunging from a prior close near 4.13 dollars to roughly 1.11 dollars after a major regulatory setback. The collapse follows fresh confirmation that the U.S. Food and Drug Administration has again declined to approve reproxalap for dry eye disease, issuing another Complete Response Letter that questions efficacy.
Shares of MVST are down about 25% in premarket trading today compared with the prior close. The slide follows a sharp reassessment of the company’s outlook as investors react to new information and recent volatility in high‑beta battery and EV names.
Solaris Energy Infrastructure’s stock SEI jumped roughly 13% in today’s session, extending a sharp recent rebound from early-March lows. The move is driven by ongoing post-earnings momentum after strong Q4 and full‑year 2025 results and raised guidance highlighted rapid growth in its power solutions business.
Shares of LMND are trading approximately +10% higher intraday on Tuesday, March 17, 2026, rising from a prior close of $57.74 to around $63.51. Primary catalyst: Morgan Stanley upgraded LMND to an 'Overweight' rating and raised its price target to $85 from $80.
Shares of ICHR surged approximately +15% intraday on Tuesday, March 17, 2026, trading near $48.98 versus a prior closing price of $42.59. The primary catalyst is a high-profile analyst upgrade by Stifel, with analyst Brian Chin upgrading the stock to Buy citing improved cyclical strength and conviction in the company's revenue and margin trajectory.
NBIS shares are down approximately 10.00% in Tuesday's session, falling from a prior close of $129.85 to around $116.87. The primary catalyst is Nebius Group's pre-market announcement of a proposed $3.75 billion convertible senior notes offering, sparking dilution concerns.
TME shares fell over 20% today, with the stock sliding from the mid‑$15s toward the low‑$13s in the wake of its Q4 2025 report and earnings call, extending a pre‑market drop of roughly 12–13%.
HUYA shares fell over 11% today, dropping from the mid‑$3 range toward the low‑$3s following the company’s Q4 2025 earnings release before the U.S. market open. Q4 total net revenues rose about 16% year over year to roughly CNY 1.74 billion, with full‑year 2025 revenues up around 7% to CNY 6.5 billion, but the market had already priced in a rebound after a difficult 2024.​
CWCO fell over 9% today, trading around the low‑$31 range versus recent levels in the mid‑$30s to near $39, as the market reacted negatively to Q4 2025 results and forward commentary. Full‑year 2025 results showed stable earnings and dividend growth but a roughly 9% decline in services revenue to about $46.3 million, reflecting a slowdown in project‑based construction work.
SMTC shares dropped over 8% today after the company reported Q4 results that met or modestly beat Street estimates but showed the slowest year‑over‑year revenue growth in several quarters, at about 9.3% to roughly $274–275 million.
AXTI shares slipped more than 6% today, reversing part of a powerful rally that had recently driven the stock to a 52‑week high above $47 and more than doubled its price year‑to‑date. Q4 2025 revenue of about $23.0 million missed consensus by roughly $1.2 million and fell 8–18% year over year and sequentially, while the company posted another GAAP net loss of around $3.5 million (–$0.08 per share).
Shares of SailPoint, Inc. (SAIL) are tumbling approximately 12% in premarket trading on March 18, 2026, after the company released its fiscal fourth-quarter and full-year 2026 results before the market opened. While Q4 revenue came in slightly above consensus at $295 million (+23% year-over-year), investors were rattled by disappointing forward guidance for fiscal 2027.
Shares of KC surged approximately +17% in premarket trading on March 18, 2026, from a prior close of $13.12 to approximately $15.35. The primary catalyst is Kingsoft Cloud's release of its unaudited Q4 and full-year 2025 financial results before the U.S. market open, which appear to have significantly exceeded analyst expectations.
AngloGold Ashanti (AU) shares tumbled approximately 7% in premarket trading on March 18, 2026, extending a multi-week downtrend that has erased nearly 20% of the stock's value since late January highs. The primary catalyst driving the decline is persistent investor concern over AngloGold's lowered 2026 production guidance, with the company projecting gold output of 2.80–3.17 million ounces — a roughly 3% decline from its 2025 production of 3.1 million ounces.
AAOI shares surged approximately 10.90% in premarket trading on March 18, 2026, rising from a prior close of $86.33 to $95.74. The primary catalyst is strong positive sentiment generated at OFC 2026 — the Optical Fiber Communications Conference and Exhibition — where Applied Optoelectronics unveiled breakthrough laser and transceiver technology for next-generation AI data center infrastructure.
LITE shares surged approximately +12% in early Wednesday trading on March 18, 2026, with the stock changing hands near $727 compared to a prior session close of $649.56. The primary near-term catalyst is Lumentum's S&P 500 index inclusion, effective March 23, 2026, triggering front-running by institutional investors and mandatory buying by passive index funds.
Shares of New Era Energy & Digital, Inc. (NUAI) are trading down approximately 17% during today's session, with the prior close sitting at $5.56. The decline follows the company's March 17 business update conference call and webcast, held after market hours, during which management discussed the recently filed fiscal year 2025 annual report (Form 10-K).
Shares of Regencell Bioscience Holdings (RGC) are up approximately +16% intraday on March 18, 2026, trading at $26.56 against a prior close of $22.97. No single company-specific press release is driving today's move; the rally is primarily fueled by retail-driven momentum and short squeeze mechanics.
A jump in the Producer Price Index from 0.3% to around 0.7% month‑over‑month signals that wholesale inflation is re‑accelerating, delaying Fed rate‑cut hopes and reviving the “higher for longer” rates narrative.business. Likely winners in this environment include energy and commodity producers (XOM, CVX, TTE, COP), inflation‑resilient financials (JPM, BAC), and real‑asset plays like pipelines and infrastructure, which can pass through higher prices; ETFs like XLE, XOP, XLF, DBA, GLD offer diversified exposure.
BGSI fell more than 11% today, pulling back from recent levels around the high‑$150s as investors reassessed the risk‑reward following the Q4 2025 print and major U.S. expansion plans. Full‑year 2025 sales rose 2.4% to US$3.14 billion, but same‑store sales declined 0.2%, while reported net earnings fell 25% to US$18.4 million due to US$22.6 million in acquisition and transformation costs.